[ad_1]
pichet_w
Qiagen (NYSE:QGEN) stated it accomplished the acquisition of DNA-biometrics firm Verogen for $150M.
Verogen develops DNA-based biometric human identification merchandise for evaluation of forensic genomic samples. The San Diego-based firm makes use of next-generation sequencing (NGS) applied sciences for human identification (HID) and forensic investigation.
Qiagen stated the acquisition bolsters its place in Human ID / forensics anchored by pattern assortment and preparation, genetic testing evaluation and workflow automation.
The deal builds upon a commercialization partnership between the 2 corporations companions on a distribution settlement in June 2021.
“Bringing collectively Verogen and Qiagen creates a novel alternative to higher assist investigators and researchers to advance forensic science and to search out lacking individuals, precisely establish suspects and exonerate the harmless,” stated Qiagen CEO Thierry Bernard.
Qiagen famous that Verogen’s sequencing and evaluation options are designed to be used on the MiSeq FGx Sequencing System from Illumina. With the acquisition, Qiagen positive factors unique distribution rights for this model of the MiSeq sequencer designed for forensics functions.
Qiagen added that it additionally positive factors full entry to Verogen’s pioneering GEDmatch database and GEDmatch PRO portal.
Qiagen stated it paid $150M in money for privately held Verogen from present reserves and presently expects about $20M of gross sales from the Verogen portfolio in 2023, constructing on about $5M of gross sales for Qiagen in 2022 from the distribution settlement.
The transaction is predicted to be dilutive to full-year 2023 adjusted EPS by about $0.03 per share and impartial to adjusted EPS in 2024, based on Qiagen.
[ad_2]
Source link
